BRIEF — Crescent Biopharma — Potential To Initiate First CR — 001 Phase 3 Study In Early 2028

Oct 15 (Reuters) — Crescent Biopharma, Inc.: Crescent Biopharma - Potential To Initiate First Cr-001 Phase 3 Study In Early 2028 Crescent Biopharma - Multiple Sac-tmt Plus Cr-001 Phase 2 Studies Ongoing In Over 700 Patients; Data Mid-2027 Crescent Biopharma -On Track To Report Initial Monotherapy Data From Ascend In Q1 2027, Including Antitumor Response For First-line Nsclc Cohort Crescent Biopharma - Apollo Phase 1/2 Trial Of Cr-002 To Commence Dosing This Quarter; Data H2 2027 Crescent Biopharma - Phase 1/2 Trial Of Cr-003 Ongoing In China; Initial Data Expected Q1 2027 Source text:... Further company coverage: CBIO.O (((Reuters.Briefs@thomsonreuters.com;));)